Company expands structural heart portfolio and begins the limited market release of a bipolar temporary pacing guidewire intended to introduce and position catheters and other interventional devices within the chambers of the heart while transmitting an electrical signal from an external pulse generator to the heart
Company expands structural heart portfolio and begins the limited market release of a bipolar temporary pacing guidewire intended to introduce and position catheters and other interventional devices.
Use of a microaxial flow pump led to a lower risk of death in patients with STEMI-related cardiogenic shock in the DanGer Shock trial, although with more adverse events.
Innovative new treatment option for patients with uncontrolled hypertension now available in the United StatesPALO ALTO, Calif. (BUSINESS WIRE) Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Par.